GlassScriptPhysician profile
Trisha G Ilumin
NPI 1407576093
$3,029.46
in general payments reported to CMS, 2019-2025
19 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $372 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $679.48 | 2024-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $631.08 | 2024-2025 | Fasenra, Airsupra, Breztri |
| United Therapeutics Corporation | $224.03 | 2024-2025 | Tyvaso, Tyvaso, Orenitram |
| Merck Sharp & Dohme LLC | $216.96 | 2024-2025 | Winrevair, Zerbaxa, Delstrigo |
| Amgen INC. | $203.35 | 2024-2025 | Tezspire |
| Genzyme Corporation | $195.43 | 2025 | |
| Inspire Medical Systems, INC. | $169.01 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.50 | 2025 | Ofev, Jascayd |
| Insmed, INC. | $145.77 | 2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $101.07 | 2024-2025 | Dupixent |
| Electromed, INC. | $59.69 | 2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $48.20 | 2025 | Opsumit, Uptravi |
| Astellas Pharma US INC | $47.22 | 2025 | Cresemba, Ambisome |
| Verona Pharma, INC. | $46.18 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $32.08 | 2024 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $24.91 | 2024 | |
| Theratechnologies INC. | $20.10 | 2024 | Trogarzo, Egrifta |
| Avadel Cns Pharmaceuticals, LLC | $18.92 | 2025 | Lumryz |
| La Jolla Pharmaceutical Company | $18.48 | 2024 | Xerava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Ilumin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.